Acorda's Fampridine-SR gets US priority review
This article was originally published in Scrip
Executive Summary
Acorda Therapeutics said the US FDA has accepted its resubmitted NDA for the multiple sclerosis therapy Fampridine-SR (4-aminopyridine), assigning it a priority review and a user fee date of October 22nd. The NDA acceptance came earlier than some analysts had expected.